One-year outcomes of percutaneous renal denervation for thetreatment of resistant hypertension： the first Chinese experience

Background As a novel device-based approach targeting the renal sympathetic nerves, percutaneous renal denervation（RDN） has been shown to be effective and safe for reducing blood pressure. However, while considerable data on RDNhave been obtained from Western populations, there is limited findings from East Asian populations. The purpose of thisstudy was to evaluate one-year outcomes of RDN for the treatment of resistant hypertension in Chinese patients.Methods Between February and August 2012, 14 patients （mean age 39＋8 years, 10 males） with resistant hypertensionunderwent successful RDN at the Fuwai Hospital. All 14 patients were followed up at 1, 3, 6 and 12 months post-procedure. Blood pressure, use of antihypertensive agents, renal function, and complications were investigated.Results Baseline values included mean office blood pressure of 164/103＋14/10 mmHg, mean 3.9＋0.6 anti-hypertensiveagents, and an estimated glomerular filtration rate of （79＋19） ml·min-1·1.73 m-2. Office blood pressure after the procedurewas reduced by -14/-10, -17/-11, -21/-12, and -24/-14 mmHg at 1, 3, 6, and 12 months respectively, and thereduction of the number of antihypertensive agents at the above corresponding time points was -1.3, -1.5, -1.7 and -1.8respectively （all P 〈0.001）. The mean reduction of 24-hour ambulatory blood pressure was similar to the reduction of officeblood pressure at the four corresponding time points. Renal function did not significantly change at any time point （all P〉0.05）. No clinical complications were observed at 12-month follow-up.Conclusion This study showed that RDN seems to be effective in reducing blood pressure of Chinese patients withresistant hypertension, with minimal adverse events at 12-month follow-up.

One-year outcomes of percutaneous renal denervation for the treatment of resistant hypertension: the first Chinese experience